A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)

A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection

开始日期2025-08-05

申办/合作机构

Vir Biotechnology, Inc.

NCT07128550

/ Recruiting临床3期

A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide

开始日期2025-07-30

申办/合作机构

Vir Biotechnology, Inc.

NCT06504485

/ RecruitingN/AIIT

Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Association With Disease Outcomes and Response to Bulevirtide Treatment

Pharmacological, single-center, non-profit observational study.
The present study is part of a cooperation project between the SC Gastroenterology and Hepatology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Milan, Italy), the University of Milan, the University of Parma and Rome Tor Vergata, funded under the call for Research Projects of Significant National Interest - 2022 PNRR Call (Prot. P2022WEXP2).
Hepatitis D virus (HDV) is a defective RNA virus, which requires the presence of hepatitis B virus (HBV) to infect liver cells and propagate. To date, the mechanisms underlying the accelerated disease progression in the natural history of Delta hepatitis are poorly understood, as is the course of the HDV-specific immune response (CD4 and CD8 T cells). As in chronic HBV and HCV infections, the outcome of chronic HDV infection appears to be dictated primarily by the host immune response, which represents a key determinant for virus control or persistence. For HBV/HDV coinfection, the role of T cells has not been well defined, as suitable animal models are lacking and so far few HDV-specific T cell epitopes have been precisely mapped, mainly limited to HLA-B alleles.
The study is divided into two substudies (cross-sectional and longitudinal). The primary objective of the cross-sectional study is to calculate the prevalence of HDV-specific T responses in patients with chronic HBV-HDV infection naïve to treatment with Bulevirtide. The primary objective of the longitudinal study is the change in the prevalence of HDV-specific T responses in patients with chronic HBV-HDV infection during treatment with Bulevirtide compared to baseline (pre-treatment).

开始日期2024-09-01

申办/合作机构

Fondazione IRCCS Ca' Granda

[+1]

100 项与布尔韦肽相关的临床结果

登录后查看更多信息

100 项与布尔韦肽相关的转化医学

登录后查看更多信息

100 项与布尔韦肽相关的专利（医药）

登录后查看更多信息

213

项与布尔韦肽相关的文献（医药）

2025-09-01·ZEITSCHRIFT FUR GASTROENTEROLOGIE

Quality of life improves during antiviral therapy with bulevirtide

Article

作者: Mrowietz, Simon Kristian ; Port, Kerstin ; Eichholz, Julia Carolin ; Deterding, Katja ; Wedemeyer, Heiner ; Dinkelborg, Katja ; Dietz-Fricke, Christopher

Abstract:

Hepatitis D virus (HDV) infection is the most severe form of viral hepatitis and has been shown to be associated with reduced quality of life. With the approval of the entry inhibitor bulevirtide, the first specific agent for HDV infection became available. Here, we report data on quality of life (QOL) before and during antiviral therapy with bulevirtide in a single center real-world cohort.We investigated QOL assessed by the Short Form 36 Health Survey (SF-36) in 25 patients undergoing antiviral treatment with bulevirtide. Surveys were completed before the beginning of antiviral therapy and up to week 152 of treatment as a long-term follow up.The study cohort included 7 women (28%) and 18 men (72%) with a median age of 46 years. Liver cirrhosis (defined as liver stiffness measurement ≥ 15.2 kPa) was present in 16 patients (64%) at the start of antiviral treatment. During the course of antiviral treatment with bulevirtide, scores for vitality, mental health and bodily pain significantly improved. The physical component score showed a minimal clinically important increase of ≥ 2.5 points in 10 patients (42%) at week 24 and in 6 patients (30% of patients with full data available) at week 48. The mental component score showed a minimal clinically important increase (≥ 2.5 points compared to baseline) in 10 patients (42%) at week 24 and in 12 patients (60%) at week 48. In the patient cohort with an improvement of physical or mental component scores at week 48, a further improvement beyond week 48 was evident in single cases but not in all patients. Importantly, changes of physical or mental component scores were not associated with virological or biochemical responses.Vitality, mental health and bodily pain improved during BLV treatment. As a sign of the good tolerability of BLV, no significant deteriorations in QOL scores were observed. Findings need to be confirmed and further evaluated in larger cohorts and longer follow-up is needed.

2025-09-01·MICROBIAL PATHOGENESIS

Update on the management of HDV infection: current events and perspectives

Review

作者: Ametrano, Luigi ; Di Fusco, Antonio ; Gentile, Ivan ; D'Agostino, Alessia ; Iuliano, Antonio ; Buonomo, Antonio Riccardo ; Pinchera, Biagio ; Trucillo, Emilia ; Esposito, Nunzia

HDV infection has long been, and continues to be, a significant challenge. Chronic liver disease related to HDV is one of the most aggressive forms of liver disease, carrying a high risk of progression to cirrhosis and decompensated liver disease. Although an estimated 12 to 72 million people worldwide have been exposed to HDV, the prevalence of HDV-related conditions is believed to be underreported, and further epidemiological studies are needed to better understand its scope. In this context, screening for anti-HDV in all HBsAg-positive individuals could help identify undiagnosed cases of HDV, regardless of known risk factors. While certain groups are at higher risk for HDV infection, more than half of individuals with HDV infection have no identifiable risk factors. Simultaneously, the risk factors for severe disease progression remain poorly defined, although persistent and/or high viral load, along with elevated cytolysis indices, appear to be linked to a more severe disease prognosis. Once HDV infection is diagnosed, treatment becomes necessary, especially given the limited therapeutic options available. Until recently, interferon-α was the only treatment option, but it came with challenges, including poor tolerability and suboptimal virological response rates. In July 2020, the European Medicines Agency (EMA) approved Bulevirtide, a new drug for the treatment of HDV. Bulevirtide not only offered a novel therapeutic option for HDV but also marked a milestone in the history of HDV treatment. However, while this new drug represents a significant advance, there are still several aspects that need further clarification and exploration.

2025-08-01·Liver International

Comparative Efficacy of Treatment Regimens for Chronic Hepatitis D Virus Infection: A Systematic Review and Network Meta‐Analysis

Review

作者: Mylona, Evangelia K. ; Shehadeh, Fadi ; Kalligeros, Markos ; Bakaloudi, Dimitra Rafailia ; Noureddin, Mazen ; Mylonakis, Eleftherios ; Dellis, Charilaos ; Ouranos, Konstantinos

ABSTRACT:

Background and Aims:

Treatment of chronic hepatitis delta virus (HDV) infection with pegylated interferon‐alpha (PEG‐IFN‐alpha) is associated with variable and often poor treatment responses. Recently, bulevirtide was approved for chronic HDV infection with promising results.

Methods:

We conducted a pairwise network meta‐analysis of five treatment regimens—bulevirtide, bulevirtide plus PEG‐IFN‐alpha, PEG‐IFN‐alpha, lonafarnib and lonafarnib plus PEG‐IFN‐alpha—by reviewing randomised studies in PubMed, EMBASE and Web of Science. A control group receiving no treatment or nucleos(t)ide analogs alone was included. Primary outcomes were virological response (undetectable HDV RNA or ≥ 2 log10 IU/mL decrease from baseline), biochemical response (ALT normalisation) and combined response (defined as fulfilment of both virological and biochemical responses), measured at end of treatment and 24 weeks post‐treatment. Odds ratios (ORs) with 95% confidence intervals (CIs) were used for analysis.

Results:

Data from 934 patients in 6 randomised studies showed that, at the end of treatment, bulevirtide plus PEG‐IFN‐alpha combination therapy was more likely to achieve virological response compared to PEG‐IFN‐alpha (OR, 8.39; 95% CI: 3.46, 20.37) and bulevirtide (OR, 6.31; 95% CI: 3.17, 12.59). Bulevirtide 10 mg plus PEG‐IFN‐alpha combination therapy was more likely to achieve virological response compared to bulevirtide 2 mg plus PEG‐IFN‐alpha combination therapy at the end of treatment (OR, 2.43; 95% CI: 1.16, 5.09). Bulevirtide 10 mg (OR, 4.43; 95% CI: 1.17, 16.83) and bulevirtide 2 mg (OR, 10.95; 95% CI: 2.51, 47.74) were more likely to achieve biochemical response compared to PEG‐IFN‐alpha at the end of treatment, but bulevirtide plus PEG‐IFN‐alpha combination therapy was not (OR, 3.24; 95% CI: 0.84, 12.50). At 24 weeks post‐treatment, bulevirtide plus PEG‐IFN‐alpha combination therapy was more likely to result in virological response compared to PEG‐IFN‐alpha (OR, 3.69; 95% CI: 1.05, 12.98) and bulevirtide (OR, 2.79; 95% CI: 1.13, 6.92), as well as biochemical response compared to PEG‐IFN‐alpha (OR, 3.23; 95% CI: 1.38, 7.56). Bulevirtide plus PEG‐IFN‐alpha combination therapy was more likely to result in combined response compared to PEG‐IFN‐alpha (OR, 6.06; 95% CI: 2.03, 18.05) and bulevirtide (OR, 4.67; 95% CI: 2.21, 9.85) at the end of treatment. At 24 weeks post‐treatment, neither bulevirtide monotherapy nor bulevirtide plus PEG‐IFN‐alpha combination therapies at various doses were more likely to achieve combined response compared to PEG‐IFN‐alpha.

Conclusions:

Bulevirtide plus PEG‐IFN‐alpha combination therapy was superior in achieving virological response, both in magnitude and duration, compared to bulevirtide or PEG‐IFN‐alpha monotherapies in patients with chronic HDV infection.

项与布尔韦肽相关的新闻（医药）

2025-09-04

·GlobeNewswire-Health Care

Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D

AZURE-2 evaluates the efficacy and safety of brelovitug as a monotherapy compared head-to-head with Hepcludex (bulevirtide) Enrollment in AZURE-1, a global pivotal clinical trial evaluating the efficacy and safety of brelovitug compared to delayed treatment, continues on track REDWOOD CITY, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced that it has enrolled the first patient in its AZURE-2 global clinical trial evaluating brelovitug (also known as BJT-778) compared to Hepcludex® (bulevirtide) for the treatment of chronic hepatitis D (CHD). The phase 3 clinical trial is part of the global registrational program for brelovitug. AZURE-2 is a randomized, controlled study evaluating brelovitug monotherapy (300 mg subcutaneous injection self-administered by participants weekly at home) compared with Hepcludex (bulevirtide) in adults with CHD. The primary endpoint is the proportion of participants who achieve a composite response at week 48, defined as undetectable hepatitis D virus RNA together with normalization of alanine aminotransferase (ALT). Elevated ALT levels are a marker of liver cell inflammation, which drives the development of liver cirrhosis and liver cancer. “Chronic hepatitis D is the most severe form of viral hepatitis, yet it remains underserved, with limited or no approved treatment options in most countries,” said Nancy Shulman, M.D., Chief Medical Officer of Bluejay Therapeutics. “The primary endpoints of the AZURE-1 and AZURE-2 trials include a composite measure of viral response and ALT normalization. Evidence from large cohort studies in hepatitis B has shown an association between delayed ALT normalization and increased risk of liver disease progression and liver cancer.1” “Bluejay continues to swiftly advance our registrational program for brelovitug in CHD,” said Keting Chu, M.D., Ph.D., Founder, Chief Executive Officer and Chairman of Bluejay Therapeutics. “We are proud to support the patients and providers in need of new hope.” AZURE-1 (NCT06907290), which was initiated in March 2025, is enrolling in the United States and other countries around the world. The AZURE-1 trial is powered to detect superiority of brelovitug treatment compared with delayed treatment. About Brelovitug (also known as BJT-778)Brelovitug is an investigational, highly potent, pan-genotypic, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) on both the hepatitis D virus (HDV) and the hepatitis B virus (HBV). Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which gives brelovitug a potentially advantageous safety profile and makes it a potentially efficacious treatment for chronic hepatitis D (CHD), a condition with urgent unmet medical need. In addition, brelovitug has shown immunomodulatory functions in chronic hepatitis B (CHB) patients, which may help to reconstitute antiviral immunity and contribute to functional cure for CHB when combined with other agents. In January 2025, brelovitug received FDA Breakthrough Therapy designation for the treatment of CHD. It has also received PRIME and Orphan designations from the European Medicines Agency. Bluejay Therapeutics owns the worldwide rights to brelovitug. About Chronic Hepatitis D (CHD) CHD, a coinfection that occurs in some people infected with the hepatitis B virus, is the most severe form of viral hepatitis due to the potential for rapid progression to liver cirrhosis, liver cancer and liver-related death. CHD affects approximately 7 million people globally. It is estimated that more than 50% of individuals with CHD will die of liver-related causes within 10 years of diagnosis. There are currently no approved treatments for CHD in the United States and most countries worldwide. About Bluejay TherapeuticsBluejay Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases. The company is currently investigating brelovitug for the treatment of chronic hepatitis D (CHD) and chronic hepatitis B (CHB) viral infections. Additionally, Bluejay is advancing several innovative programs with the goal of developing a combination regimen to achieve a functional cure for chronic hepatitis B, including a proprietary TLR9 agonist (cavrotolimod) and a liver-targeted HBV transcript inhibitor (BJT-628). The company is also investigating BJT-188, a preclinical liver-targeted fatty acid synthase (FASN) inhibitor, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). For more information on Bluejay Therapeutics, please visit the company’s website at www.bluejaytx.com or follow the company on LinkedIn. Contact: Dan Boyle Orangefiery media@orangefiery.com 818-209-1692 1 https://pubmed-ncbi-nlm-nih-gov.libproxy1.nus.edu.sg/31895708/

突破性疗法临床3期孤儿药

2025-08-10

·药事纵横

吉利德：重仓多年的CAR-T仍无法挑起大梁，营收依然高度依赖艾滋病业务

2025年8月5日，吉利德科学公布了2025年第二季度财务业绩。尽管整体营收仅增长2%，但核心HIV业务表现亮眼，而新冠药物Veklury（瑞德西韦）和细胞疗法产品则持续下滑。公司上调全年营收和盈利指引，并宣布新的股票回购计划，显示出对未来增长的信心。核心财务数据 1. 营收与盈利总营收71亿美元，同比增长2%，略低于市场预期。产品销售额70.5亿美元，同比增长2%，剔除Veklury后增长4%至69亿美元。GAAP每股收益（EPS）1.56美元，同比增长21%（2024年Q2为1.29美元）。Non-GAAP每股收益2.01美元，与去年同期持平，主要受研发费用增加影响。 2. 现金流与资本配置现金及等价物71亿美元，较2024年底的100亿美元下降，主要由于17亿美元过渡税支付。经营现金流8.27亿美元，受税收影响有所下降。股息支付9.94亿美元，股票回购5.27亿美元。董事会批准新一轮60亿美元股票回购计划，显示管理层对长期价值的信心业务板块表现 1. HIV务：Biktarvy增长强劲，Yeztugo获批成亮点HIV产品销售额51亿美元，同比增长7%，占总营收72%。Biktarvy（比克替拉韦/恩曲他滨/丙酚替诺福韦）：全球销售额35亿美元，同比增长9%，美国市场贡献28亿美元（+8%）。欧洲市场增长16%（4.29亿美元），新兴市场增长9%（3.02亿美元）。 Descovy（恩曲他滨/丙酚替诺福韦）：销售额6.53亿美元，同比增长35%，主要因价格上涨及需求增加。 Yeztugo（lenacapavir，长效HIV预防药）：FDA批准全球首款半年一次HIV暴露前预防（PrEP）方案，预计2025年下半年上市。与全球基金（Global Fund）达成协议，未来三年向低收入国家提供200万人份药物。 2. 肝病业务：Livdelzi增长抵消HCV下滑肝病产品销售额7.95亿美元，同比下降4%。HCV（丙肝药物）收入下滑，主要因市场萎缩及仿制药竞争。Livdelzi（seladelpar，原发性胆汁性胆管炎药物）：销售额增长显著，但具体数据未披露。Hepcludex（bulevirtide，丁肝药物）：欧洲市场表现稳定，但美国尚未获批。 3. 肿瘤业务：Trodelvy增长，但CAR-T疗法遇阻肿瘤产品销售额8.49亿美元，同比增长1%。Trodelvy（戈沙妥珠单抗，三阴性乳腺癌药物）：销售额3.64亿美元，同比增长14%，主要因需求增加及库存调整。ASCENT-03 III期研究结果积极，可能拓展一线治疗适应症。CAR-T细胞疗法（Yescarta/Tecartus）：整体销售额4.85亿美元，同比下降7%。Yescarta（大B细胞淋巴瘤）：销售额3.93亿美元（-5%），面临市场竞争压力。Tecartus（套细胞淋巴瘤）：销售额9200万美元（-14%），需求下降明显。 4. 其他业务：Veklury持续萎缩 Veklury（瑞德西韦）销售额1.21亿美元，同比暴跌44%，因COVID-19住院率下降。其他产品（包括AmBisome等）销售额2.02亿美元，同比下降28%。研发与战略进展 1. 关键研发里程碑 HIV领域：Yeztugo（长效PrEP）获FDA批准，并获WHO指南推荐。PURPOSE 1 & 2试验数据支持其在孕妇、青少年等群体的应用。GS-1720/GS-4182（HIV治疗候选药）遭FDA临床暂停，影响研发进度。肿瘤领域：Trodelvy联合Keytruda的ASCENT-04研究数据积极，可能拓展PD-L1+患者市场。与Kymera合作开发CDK2降解剂，拓展肿瘤管线。炎症领域：Livdelzi长期安全性数据（ASSURE研究）支持其在肝病领域的潜力。 2. 成本控制与运营优化 Non-GAAP产品毛利率86.9%，同比提升90个基点，受益于产品组合优化。研发费用15亿美元，同比增长9%，主要因临床制造及研究活动增加。 SG&A费用持平，促销支出增加被企业费用下降抵消。 2025年全年指引上调吉利德上调全年财务预期，反映核心业务的稳健表现：指标 2025年新指引此前指引变动产品销售额 283-287亿美元 282亿美元 +1.8% 剔除Veklury后销售额 273-277亿美元 268亿美元 +3.7% GAAP每股收益 5.85-6.15美元 5.65-7.70美元中值上调 Non-GAAP每股收益 7.95-8.25美元 7.70-8.10美元上限提高市场影响与未来展望 1. 投资者反应财报公布后，吉利德股价盘后小幅波动，市场关注点包括： Yeztugo的商业化潜力，能否成为新的增长引擎。 CAR-T疗法竞争加剧，Yescarta能否抵御诺华、百时美施贵宝等对手。 Trodelvy的适应症拓展，能否在乳腺癌市场占据更大份额。 2. 长期战略挑战依赖HIV业务：Biktarvy占比过高，需加速肿瘤和炎症管线的贡献。细胞疗法市场压力：需优化制造及定价策略以应对竞争。政策风险：美国IRA法案可能影响药品定价，需调整市场策略。药事纵横投稿须知：稿费已上调，欢迎投稿

免疫疗法细胞疗法财报临床3期临床失败

2025-08-07

·EndPoints

Gilead says it 'hit the ground running' on its long-acting HIV shot launch

The launch of Gilead’s groundbreaking HIV prevention shot is progressing “well ahead of our expectations,” the company’s chief commercial officer said Thursday. Yeztugo, the first-ever twice-yearly prevention shot available in the US, was approved in June for pre-exposure prophylaxis (PrEP) in adults and adolescents. The first prescription was written hours after the approval, and the first injection was administered within days, Gilead chief commercial officer Johanna Mercier told investors on the company’s second-quarter earnings call. “The team has been executing what I consider to be the best-planned commercial launch I have seen to date,” she said, adding later that Gilead “hit the ground running.” Yeztugo is also known as lenacapavir, which was first approved by the FDA in 2022 as Sunlenca for the treatment of HIV. Other options for prevention include ViiV Healthcare’s shot Apretude, which is administered every two months, or daily pills for PrEP. In an effort to differentiate Yeztugo, Gilead has positioned the injection as a more convenient option that could drive stronger patient adherence. The company declined to provide exact figures on the number of Yeztugo prescriptions written or the number of doses administered so far. But Mercier said on the call that Gilead is “extremely pleased with the feedback from both clinicians and consumers, as well as the progress of our early discussions with payers.” Gilead’s HIV product sales increased 7% in the second quarter, compared to the same period in 2024, reaching $5.1 billion. That includes a 35% sales spike for Descovy, a tablet that can be used for HIV prevention and in combination with other medicines to treat the virus. Biktarvy, Gilead’s other oral treatment for HIV, saw a 9% sales increase. The company now expects HIV sales to grow about 3% in 2025, as opposed to prior expectations of flat year-over-year revenue, partly driven by strong sales of Biktarvy and Descovy. CFO Andrew Dickinson said Gilead isn’t updating its assumptions for Yeztugo revenue in the second half of 2025 “at this time,” despite being “very encouraged by the launch dynamics” so far. Gilead raised its full-year sales guidance to $28.3 billion to $28.7 billion, slightly up from prior expectations of $28.2 billion to $28.6 billion. That takes into account lowered expectations for the company’s Covid-19 antiviral Veklury, as the company reports lower rates of Covid-related hospitalizations. Elsewhere in its news release, Gilead reported a $190 million impairment charge related to assets from its $1.7 billion acquisition of MYR in 2020. Hepcludex, MYR’s hepatitis delta virus treatment approved in Europe, was at the center of the buyout. However, the FDA rejected the drug in 2022 over “manufacture and delivery” concerns, Gilead said at the time. It now has a biologics license application pending, according to Gilead’s second-quarter earnings slides . When asked for more details, a Gilead spokesperson said the partial impairment charge was “related to the changing competitive dynamics in indications Hepcludex is being developed for.”

上市批准并购

100 项与布尔韦肽相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11878	布尔韦肽	J05A	DB15248

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
病毒感染	加拿大	Gilead Sciences Canada, Inc.	2025-08-01
慢性丁型肝炎	欧盟	Gilead Sciences Ireland UC	2020-07-31
慢性丁型肝炎	冰岛	Gilead Sciences Ireland UC	2020-07-31
慢性丁型肝炎	列支敦士登	Gilead Sciences Ireland UC	2020-07-31
慢性丁型肝炎	挪威	Gilead Sciences Ireland UC	2020-07-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
丁型肝炎	临床3期	-	Gilead Sciences, Inc.	-
丁型肝炎	临床3期	-	Atos SE	-
慢性乙型肝炎	临床2期	俄罗斯	Hepatera LLC	2016-04-01
慢性丙型肝炎	临床2期	-	Hepatera LLC	2014-02-13
乙型肝炎	临床2期	-	Atos SE	-
胆汁性肝硬化	临床前	德国	MYR GmbH	2018-04-04
血脂障碍	临床前	德国	MYR GmbH	2018-03-24
非酒精性脂肪性肝炎	临床前	德国	MYR GmbH	2018-03-20

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05760300 (CTgov)	临床1期	慢性丁型肝炎	41	Bulevirtide (BLV) (Group A: BLV 2 mg (Severe RI Group))	鑰鏇齋膚製膚壓衊選餘(醖壓築選窪築窪鹽廠鏇) = 製鏇製構夢襯鹹廠選築膚衊廠襯願構選築遞製 (構窪製繭願壓襯蓋糧膚, 29.8) 更多	-	2025-09-18
				Bulevirtide (BLV) (Group A: BLV 2 mg (Matched Control))	鑰鏇齋膚製膚壓衊選餘(醖壓築選窪築窪鹽廠鏇) = 積廠衊鑰艱遞選遞膚糧膚衊廠襯願構選築遞製 (構窪製繭願壓襯蓋糧膚, 32.6) 更多
NCT03852719 (MYR301, Company_Website) 人工标引	临床3期	丁型肝炎	-	Bulevirtide	顧膚製築簾襯淵繭餘鏇(糧鬱觸襯醖衊鏇衊襯齋) = 範蓋遞構鬱製鑰製鹽憲蓋鏇網鏇糧衊壓壓觸獵 (範簾觸膚齋繭壓獵鏇獵 ) 更多	积极	2025-05-07
NCT02888106 (Pubmed \| Liver Int)	临床2期	慢性丁型肝炎	-	BLV 2 mg once daily + Peg‐IFNα‐2a 180 μg once weekly	繭遞夢獵壓鏇構膚醖艱(壓構鹹鏇鏇築網簾構窪) = 餘醖蓋窪構構醖餘醖顧鑰憲齋積鹽簾廠膚壓鏇 (餘鬱齋鏇鑰蓋遞窪餘艱 )	积极	2025-02-01
				BLV 5 mg once daily + Peg‐IFNα‐2a 180 μg once weekly	繭遞夢獵壓鏇構膚醖艱(壓構鹹鏇鏇築網簾構窪) = 製積鏇製齋壓網廠廠鏇鑰憲齋積鹽簾廠膚壓鏇 (餘鬱齋鏇鑰蓋遞窪餘艱 )
NCT03852433 \| NCT02888106 \| NCT03852719 (MYR301;MYR203;MYR204, Pubmed \| Liver Int)	临床2/3期	慢性丁型肝炎	269	Bulevirtide 2 mg	構衊鑰選範鏇齋簾鑰齋(淵願衊範廠淵襯構鑰觸) = Neither hepatic decompensation nor death occurred 鹹膚鹽襯憲鏇範網壓簾 (蓋鑰積夢襯觸窪鬱遞醖 ) 更多	积极	2024-12-08
				Bulevirtide 10 mg
NCT03546621 \| NCT02888106 \| NCT03852719 (MYR301, Pubmed) 人工标引	临床2期	慢性丁型肝炎 HBsAg-positive hepatocytes	126	Bulevirtide 2 mg/day	糧糧醖築膚齋糧艱壓衊(廠夢願壓壓鬱壓簾窪餘) = 鏇簾獵襯窪廠鑰夢積廠膚壓醖獵襯願艱鏇糧構 (夢鏇網網鏇窪憲糧蓋構 ) 更多	积极	2024-02-08
				Bulevirtide 5 mg/day	糧糧醖築膚齋糧艱壓衊(廠夢願壓壓鬱壓簾窪餘) = 鬱艱繭醖蓋糧積膚範簾膚壓醖獵襯願艱鏇糧構 (夢鏇網網鏇窪憲糧蓋構 )
AASLD2023	N/A	冠状动脉疾病	128	BLV 2 mg	觸積齋糧鏇鹽糧淵遞醖(獵淵範鏇廠觸憲構構獵) = 範構遞壓簾鹽製醖餘壓窪廠鹹鹽網繭衊網膚齋 (願艱壓艱襯鹹築獵衊廠 ) 更多	-	2023-11-10
				BLV 10 mg	觸積齋糧鏇鹽糧淵遞醖(獵淵範鏇廠觸憲構構獵) = 鏇選淵糧廠窪選窪窪壓窪廠鹹鹽網繭衊網膚齋 (願艱壓艱襯鹹築獵衊廠 ) 更多
AASLD2023	N/A	-	141	Bulevirtide 2mg	鹹網範淵築範淵選製築(積積壓衊觸鬱壓衊繭鬱) = 選遞夢製獵壓襯獵淵顧襯襯窪壓衊顧廠構範蓋 (範齋窪醖壓廠顧簾鹹淵 ) 更多	-	2023-11-10
				Bulevirtide 10mg	鹹網範淵築範淵選製築(積積壓衊觸鬱壓衊繭鬱) = 餘選艱齋鏇鑰繭獵遞窪襯襯窪壓衊顧廠構範蓋 (範齋窪醖壓廠顧簾鹹淵 ) 更多
NCT05962307 (HEP4Di, AASLD2023)	N/A	丁型肝炎	97	Bulevirtide 2 mg/day	餘鹹願窪鬱窪顧觸鹽憲(鑰構糧簾衊顧醖醖衊壓) = 壓餘齋簾齋觸獵齋糧簾鹹鬱夢膚壓鏇壓築選淵 (襯願觸獵夢網觸網衊窪 ) 更多	-	2023-11-10
NCT05928000 \| NCT03852719 (MYR 301, Pubmed)	临床3期	慢性丁型肝炎	150	Bulevirtide 2 mg/day	齋鹹餘艱淵築衊壓獵範(鏇淵夢鹹醖網鏇範鏇壓) = more common in the 2-mg and 10-mg groups combined than in the control group 願襯壓鏇製簾鑰鬱夢鑰 (鹹網觸糧衊網醖製築積 ) 更多	积极	2023-06-22
				Bulevirtide 10 mg/day